RNPC3 and glioblastoma: Moreover, the nanosystem significantly improved the pharmacokinetics, BBB transcytosis, and brain tumor targeting of Cas12a/crRNA RNP, which led to the substantial inhibition of GBM progression resulting from the crEGFR and crPLK1 synergism.